首页 > 文章详情

【Journal of Oncologynews】乳腺癌文献荟萃-001

2017年03月20日

本期主编：DDL

1、March 2, 2017

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast CancerThe Randomized Clinical FinXX Trial

早期乳癌辅助化疗方案中，在蒽环类或紫杉类药物的基础之上，加入卡培他滨能否对生存获益？FinXX研究发现加入卡培他滨并不能提高生存，三阴乳癌患者或可获益。

http://jamanetwork.com/journals/jamaoncology/fullarticle/2606438

2、March 9, 2017

Association of the Timing of Pregnancy With Survival in Women With Breast Cancer

越来越多的女性在罹患乳癌之时或患病后怀孕，本文研究怀孕对这些乳癌妇女生存期的影响。研究表明，怀孕不会对生存期产生负面影响，若确诊后6月之后再计划怀孕，死亡风险较低。

http://jamanetwork.com/journals/jamaoncology/fullarticle/2608281

1、Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

Troponin I和T(肌钙蛋白)和脑钠尿肽在检测早期Her2阳性乳癌对赫赛汀心脏毒性反应中的作用。结果显示，治疗前Troponin I和T升高对心脏毒性有相关性。

https://www.ncbi.nlm.nih.gov/m/pubmed/28199174/

2、JCO 14 Mar

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

靶向三阴乳癌trop-2的抗体偶联药物Sacituzumab govitecan在复发难治三阴乳癌患者的临床I期研究。结果显示，该药耐受性良好，反应较持久，值得进行接下来进一步研究。

https://www.ncbi.nlm.nih.gov/m/pubmed/28291390/

24 February 2017

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

PAMELA研究: 早期Her2阳性乳癌无化疗双Her2靶向疗效预测: Her2高表达亚型是病理完全缓解的相关因素

http://thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(17)30021-9.pdf

责任编辑：肿瘤资讯—Lilith